Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ensemble Therapeutics has initiated a research collaboration with Boehringer Ingelheim to discover drug candidates for a new class of small molecule drugs, macrocycles against several pharmaceutical targets specified by Boehringer Ingelheim.
Subscribe to our email newsletter
As part of the agreement, Ensemble will receive upfront payment, research funding and may receive nearly $186m milestones payments up on commercial success of multiple drug products along with royalties on future products sales.
The companies will deploy Ensemble’s proprietary drug discovery platforms, along with Ensemblin collection of about 5 million macrocycles for discovery and advancement of new drug candidates.
The agreement also provides Boehringer Ingelheim with rights to develop and commercialize substances arising from the collaboration.
Ensemble Therapeutics CEO Michael Taylor said, "This collaboration with Boehringer Ingelheim builds on Ensemble’s business strategy to partner with leading pharmaceutical companies and further validates the wide-ranging potential of our Ensemblin drug discovery platforms while providing Ensemble with additional funding to advance our own internal pipeline."
Ensemblins are a new class of synthetic macrocycles developed by Ensemble using its proprietary chemistry platforms, including DNA-Programmed Chemistry.